Psilocybin-Research.com Research. Clarity. Progress.
Preparing publication tracker
Psilocybin-Research.com Research. Clarity. Progress.

Psilocybin Research Publication Tracker

Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.

Database up to date Last update: Jul 2, 2026 20:42 UTC
Indexed records 3,966 SQLite literature index
Published 3,201 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,560 64.5% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 264 6.7% Active
PsyArXiv 216 5.4% Active
Crossref 161 4.1% Active
bioRxiv 142 3.6% Active
Publication timeline 3,063 dated records
3,063 records since 2020
Annual records Cumulative line
3,966Total Publications
3,825Psilocybin Records
551Psilocin Records
Search Matches
384Journals
66Research Topics

Research search

Reset all
Substances
Date range quick select

Advanced filters

Refine the current publication search without losing source and evidence-status context.

Use these only when the initial search is too broad. Filters are source-aware and preserve preprint, clinical trial, review, protocol, and published distinctions.

Evidence status
Current display No search or filter specified Showing the latest indexed records until a keyword search is submitted.

Latest Publications

Most recently published records currently stored in SQLite.

1-20
Last updated: Jul 2, 2026 20:42 UTC
Checking for newly published papers…

Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress

Neuropsychopharmacology Reports · 2026-08-31

Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki

Crossref Published psilocybinpsilocin DepressionAnxietyReceptor PharmacologyResilienceAnimal StudyTreatment-Resistant Depression Animal Study

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Unknown journal · 2026-06-30

Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y.

Europe PMC Published psilocybin DepressionAnxietyPTSDEmotional ProcessingClinical TrialReview Article Clinical Trial

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.

Unknown journal · 2026-06-30

Pasquini L, Vohryzek J, Escrichs A, Perl YS, Ponce-Alvarez A, Idesis S, Girn M, Roseman L, Mitchell JM, Gazzaley A, Kringelbach M, Nutt DJ, Lyons T, Carhart-Harris RL, Deco G.

Europe PMC Published psilocybin DepressionEating DisordersBrain ImagingMechanism of ActionReceptor PharmacologyAgingHealthy Volunteers Other

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

Unknown journal · 2026-06-30

Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD.

Europe PMC Published psilocybin Clinical TrialRandomized Controlled TrialSystematic ReviewReview Article Randomized Controlled Trial
Page 6 of 199

A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease

This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being. The main questions it aims to answer are, does psilocybin: 1. Acutely increase complexity of EEG activity in older adults with low well-being, as modulated by the presence...

ClinicalTrials.gov 2026-06-07 Jennifer Mitchell
ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingMechanism of ActionBiomarkersAgingWellbeingAnimal StudyHealthy VolunteersOlder AdultsSafetyInflammation Clinical Trial Anhedonia in Healthy VolunteersOlder Adults (50-90 Years)

Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice.

Psychedelic drugs are poised to become mainstream treatments, yet we lack a circuit-level account of how they reshape brain activity. Emerging evidence suggests that multiple psychedelic compounds modulate activity in the brain's default mode network (DMN), often interpreted as either increased or decreased bottom-up hierarchical processing. Most imaging stu...

Unknown journal 2026-06-07 Pines AR, Zhang X, Kochalka J, Vesuna SS, Kauvar IV, Rajasekharan D, Reneau TR, Akiki TJ, Hack LM, Siegel JS, Williams LM.
Europe PMC Published psilocybin Brain ImagingDefault Mode NetworkAgingAnimal Study Animal Study BrainCerebral Cortex

Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling

The main purpose of this study is to gain a better understanding of the distinct mental states and physical reactions that can arise during a psychedelic experience. By repeatedly assessing the same participants in an MRI while under the effects of psilocybin, the investigators want to identify reliable brain and body reactions arising during these psychedel...

ClinicalTrials.gov 2026-06-04 Robin Carhart-Harris, PhD, MA
ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingAgingClinical TrialHealthy Volunteers Clinical Trial Psychedelic ExperiencesNeuroimaging

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder. Treatment-resistant depression (TRD) is a serious mental health problem in Veterans, frequently comorbid with post-traumatic str...

ClinicalTrials.gov 2026-06-04 VA Office of Research and Development
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionPTSDRandomized Controlled TrialTreatment-Resistant DepressionVeteransSafetyAdverse Events Randomized Controlled Trial Major DepressionPsilocybin

Phylogenomic systematics of Lanmaoa (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage.

The genus Lanmaoa is a globally distributed, economically important group of mushroom-forming fungi in the family Boletaceae containing edible and psychoactive species. Despite the growing interest in its hallucinogenic properties, the fundamental systematics of this genus remains poorly resolved due to limited taxon sampling and limited genetic characteriza...

Unknown journal 2026-06-04 Domnauer C, Dentinger BTM.
Europe PMC Published psilocybin Genomics Other

Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity.

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition in which prenatal stress and long-lasting disruptions of excitatory-inhibitory (E/I) balance have been implicated as key vulnerability factors. Although established pharmacological and behavioral treatments are effective for many individuals, they are not universally ...

Unknown journal 2026-06-04 Ahmadian-Moghadam S, Roshan-Milani S, Saboory E.
Europe PMC Published psilocybin AddictionNeuroplasticityBrain ImagingMechanism of ActionBiomarkersAgingEmotional ProcessingClinical TrialAnimal StudySafety Clinical Trial

Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy.

Background: Understanding the benefits of psychedelic-assisted therapy (PAT) will require scientific attention to the causal interaction between the therapeutic context and process. Measuring what actually happens during PAT in large-scale studies will be an essential component of this work. Objective: We aim to develop and preliminarily evaluate the feasibi...

Unknown journal 2026-06-04 Tarbi EC, Bhatia I, Balach N, Buehler S, Demeo-Meres M, Gramling C, Thambi T, Hart J, Reblin M, Rizzo DM, Gramling R, Agrawal M, Manetta E.
Europe PMC Published psilocybin Clinical TrialDrug Interactions Clinical Trial

A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.

BackgroundWe know little about the extent psychedelic substances are consumed therapeutically and/or discussed with medical professionals despite renewed global interest in these substances.MethodsWe examined self-reported responses from the 2023 International Cannabis Policy Study (ICPS) in repeated cross-sectional surveys in Canada, the United States, Aust...

Unknown journal 2026-06-04 Graham M, Ge Y, Pacula RL, Pessar SC, Wilkins C, Hall W, Hammond D.
Europe PMC Published psilocybin Mechanism of ActionClinical TrialObservational StudyAdolescentsAdverse Events Clinical Trial HumansN-Methyl-3

Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study

This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD. Aim 1: To examine the effects of two doses of psilocy...

ClinicalTrials.gov 2026-06-03 Yale University
ClinicalTrials.gov CLINICAL TRIAL psilocybin OCDMechanism of Action Clinical Trial Obsessive-Compulsive DisorderPsilocybin

2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers

One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design. Depending on the study arm, participants will either receive an inactive placebo or up to 25mg psilocybin (oral dose), in one of two set and setting con...

ClinicalTrials.gov 2026-06-03 Robin Carhart-Harris, PhD, MA
ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityWellbeingEmotional ProcessingHealthy VolunteersDrug Interactions Clinical Trial Healthy Participants With Lower-than-average Mental Well-beingPsilocybin

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.

Chronic pain is common, costly, and for many, remains inadequately treated by existing pharmacologic and non-pharmacologic approaches. In parallel with growing dissatisfaction with conventional therapies, classic serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ayahuasca, N,N-dimethyltryptamine (DMT), and mescaline, administer...

Unknown journal 2026-06-03 Boehnke KF, Pouyan N, Aday JS.
Europe PMC Published psilocybin Chronic PainHeadache / MigraineNeuroplasticityMechanism of ActionClinical TrialReview ArticleObservational StudyAnimal StudyHealthcare WorkersSafetyDrug InteractionsContraindicationsInflammation Clinical Trial

Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report.

BackgroundThis case describes a substance-induced manic episode with psychotic features in which interaction with an AI (artificial intelligence) chatbot appeared to corroborate and reinforce the patient's delusional thought content and to contradict medical advice. Excerpts from the patient's interactions with the AI chatbot provide novel clinical insight i...

Unknown journal 2026-06-03 Shah S, Morrin H.
Europe PMC Published psilocybin AddictionSpiritualityCase ReportHealthcare WorkersSafetyDrug Interactions Case Report

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.

BackgroundPsilocybin has demonstrated promise for improving depressive symptoms in treatment-resistant depression, but its effects on anxiety, quality of life, functioning, and posttraumatic stress symptoms are less well studied. This study reports exploratory findings from an open-label trial in Veterans with TRD.MethodsParticipants received a single 25-mg ...

Unknown journal 2026-06-03 Kelly CM, Fradet M, Bostian CM, Donnelly A, Ellis S, Ostacher M, Aaronson S, Suppes T.
Europe PMC Published psilocybin DepressionAnxietyPTSDEmotional ProcessingMystical ExperienceClinical TrialTreatment-Resistant DepressionVeterans Clinical Trial

Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.

Subjective tinnitus is a common auditory disorder characterised by the subjective perception of noise in the absence of external sound sources. Its prevalence has been rising annually due to noise exposure, medication misuse, and population ageing. Current tinnitus treatments employ antidepressants, anticonvulsants, and vasodilators, yet most demonstrate lim...

Unknown journal 2026-06-03 Lu S, Zhang Z, Xue X, Jiang Y, Zhang C, Liu P, He D, Shen W, Yang S, Wang F.
Europe PMC Published psilocybin DepressionAnxietyEnd-of-Life DistressNeuroplasticityMechanism of ActionReceptor PharmacologyAgingClinical TrialReview ArticleAdverse Events Clinical Trial

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.

Background/Objectives: Psilocybin-assisted therapy (PAT) is a promising intervention to alleviate existential distress among patients with advanced cancer receiving palliative care. However, evidence on how to integrate PAT into routine oncology and palliative care services remains scarce. This study aimed to examine real-world PAT implementation, identify f...

Unknown journal 2026-06-02 Dorval M, Audet-Croteau V, Chang SL, Masse-Grenier M, Tremblay A, Bénard E, Chapdelaine A, Garel N, Guertin JR.
Europe PMC Published psilocybin End-of-Life DistressMechanism of ActionCancer PatientsHealthcare Workers Other

The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults

The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects o...

ClinicalTrials.gov 2026-06-01 University of Calgary
ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyBiomarkersWellbeingPersonality ChangeClinical Trial Clinical Trial Investigating the Importance of the Subjective Psychedelic ExperiencePsilocybin high-dose

Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults

Abstract Background Prolonged grief disorder (PGD) is a clinically distinguishable bereavement-related condition characterized by persistent yearning, identity disruption, and impaired functioning, formalized in DSM-5-TR and ICD-11 (6L72) and empirically distinguishable from but frequently co-occurring with major depressive disorder. Approximately 7 to 10 pe...

Research Square 2026-06-01 Carter D, Reardon I, Swain J, Vando L.
Europe PMC PREPRINT (not peer reviewed) psilocybin DepressionChronic PainEmotional ProcessingRandomized Controlled TrialObservational StudySafetyAdverse Events Randomized Controlled Trial

Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy.

Psilocybin, the main psychoactive compound in Psilocybe cubensis mushrooms, has gained considerable attention for its therapeutic potential. Current research focuses only on isolated psilocybin, neglecting the broader pharmacological and cultural use of the whole mushroom. This perspective advocates for an integrative approach that includes standardised P. c...

Unknown journal 2026-06-01 Ona G, Llagostera C, Alvarez O, Dueñas RM, González D, Soto-Angona O.
Europe PMC Published psilocybin DepressionOCDNeuroplasticityReview ArticleAnimal StudyMetabolomics Review Article

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Limit: 5000 characters. Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as r...

ClinicalTrials.gov 2026-05-31 Centre for Addiction and Mental Health
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionNeuroplasticityBrain ImagingReceptor PharmacologyAgingClinical TrialRandomized Controlled TrialHealthy VolunteersTreatment-Resistant Depression Clinical Trial Treatment Resistant DepressionPsilocybin 25 mg

Live source coverage

3,966 indexed records across 8 active sources.

3,201Published
478Preprints
287Clinical trials
  1. Europe PMC 2,560 records · 64.5%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 264 records · 6.7%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 161 records · 4.1%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.